CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00318136
NCT00318136Phase 2Completed
CompareCT.gov

A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer

Genentech, Inc.·interventional·Posted Apr 26, 2006·Updated May 11, 2010

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, Carboplatin, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 47 participants.

Detailed Summary

This is an open-label, single-arm, multicenter pilot study to evaluate the safety and efficacy of carboplatin/paclitaxel+bevacizumab in subjects with locally advanced (Stage IIIb with pleural effusion/pericardial effusion), Stage IV, or recurrent squamous Non-Small Cell Lung Cancer (NSCLC) who have not received prior systemic therapy for metastatic disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 26, 2006
Enrollment StartSep 1, 2005
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.2 years ago

Interventions

Bevacizumabdrug

15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3

Carboplatindrug

Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles

Paclitaxeldrug

Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles